0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover345.34%IV-133.28%PremiumDec 20, 2024Expiry Date8.57Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9622Delta0.0314Gamma0.75Leverage Ratio-0.0162Theta-0.0014Rho-0.72Eff Leverage0.0007Vega
Mercer International Stock Discussion
Mercer International Inc. Announces Preliminary Results for the Third Quarter of 2024 and Earnings Conference Call Details
Mercer International Inc. (Nasdaq: MERC) reported preliminary financial results for Q3 2024. Key highlights include:
- Revenues: $502.1 million
- Operating income: $8.8 million
- Operating EBITDA: $50.5 million
- Net loss: $17.6 million
- Liquidity: ~$554 million
The company faced unscheduled downtime at its mills, impacting pulp productio...
• $A.O. Smith (AOS.US)$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum (CPE.US)$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $Dun & Bradstreet (DNB.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
• $Enanta Pharmaceuticals (ENTA.US)$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $Corning (GLW.US)$ : CFRA Upgrades to Strong Buy ...
The oral drug, molnupiravir, is said to ultimately stop the replication of the virus by introducing a different mechanism in the genetic material, but it could affect growing human cells.
??
No comment yet